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Abstract
Background and Aims: Non-adherence to anti-tumour necrosis factor [TNF] agents in patients with 
inflammatory bowel disease [IBD] is a serious problem. In this study, we assessed risk factors for 
non-adherence and examined the association between adherence to anti-TNF agents and loss of 
response [LOR].
Methods: In this multicentre, 12-month observational study, outpatients with IBD were included. 
Demographic and clinical characteristics were recorded. Adherence was measured with the Modified 
Morisky Adherence Scale-8 [MMAS-8] and 12-month pharmacy refills [medication possession 
ratio, MPR]. Risk factors included demographic and clinical characteristics, medication beliefs, 
and illness perceptions. Cox regression analysis was performed to determine the association 
between MPR and LOR to anti-TNF, IBD-related surgery or hospitalisation, dose intensification, or 
discontinuation of anti-TNF.
Results: In total, 128 patients were included [67 infliximab, 61 adalimumab], mean age 37 ( ± 
standard deviation [SD] 14) years, 71 [56%] female. Median disease duration was 8 (interquartile 
range [IQR] 4–14) years. Clinical disease activity was present in 41/128 [32%] patients, 36/127 [28%] 
patients had an MMAS-8 < 6 [‘low adherence’], and 25/99 [25%] patients had an MPR < 80% [non-
adherence]. Risk factors for non-adherence included adalimumab use (odds ratio [OR] 10.1, 95% 
confidence interval [CI] 2.62–40.00), stronger emotional response [OR 1.16, 95% CI 1.02–1.31], 







and shorter timeline perception, i.e. short perceived illness duration [OR 0.60, 95% CI 0.38–0.96]. 
Adherence is linearly and negatively [OR 0.14, 95% CI 0.03–0.63] associated with LOR.
Conclusion: Non-adherence to anti-TNF agents is strongly associated with LOR to anti-TNF 
agents, adalimumab use, and illness perceptions. The latter may provide an important target for 
interventions aimed at improving adherence and health outcomes.
Keywords:  Inflammatory bowel disease; adherence; predictors; illness perceptions; medication beliefs
1. Introduction
The introduction of anti-tumour necrosis factor [TNF] agents, 
including infliximab and adalimumab, has greatly improved the 
treatment options in patients with Crohn’s disease [CD] and ulcera-
tive colitis [UC]. Both agents are highly efficacious for induction and 
maintenance of remission1 and have been shown to reduce rates of 
hospitalisation and surgery.2,3,4
In clinical practice, non-adherence to anti-TNF agents in patients 
with inflammatory bowel disease [IBD] ranges from 17% to 45%,5,6 
and is associated with higher rate of hospitalisation and increased 
healthcare costs.7,8 Several factors have been associated with non-
adherence to anti-TNF agents in IBD, including female gender, 
smoking, maintenance dosing, constraints related to treatment, anxi-
ety, and moodiness.5,6
Despite our increased understanding of adherence, several con-
troversies still exist. Non-adherence is generally defined as taking less 
than 80% of medication, but this definition may not be applicable to 
anti-TNF agents.9,10 Additionally, no prospective studies to date have 
evaluated the association between adherence and loss of response 
to anti-TNF agents. Finally, no consistent association between the 
above-mentioned risk factors and non-adherence to anti-TNF agents 
has been found and few of them can be modified.11,12
Treatment beliefs and illness perceptions are modifiable fac-
tors and have been consistently associated with non-adherence to 
medication across a range of chronic illnesses, including IBD.13,14,15,16 
Treatment beliefs constitute patients’ beliefs about the necessity 
of their medication for controlling their illness and their concerns 
about potential side effects.17 Illness perceptions constitute patients’ 
views, cognitive or emotional, about several components of the ill-
ness such as the causes, clinical course, daily consequences, curabil-
ity, and emotional impact.18
Therefore, in this multicentre prospective study we assessed: 1] 
risk factors, including treatment beliefs and illness perceptions, for 
non-adherence to anti-TNF agents; and 2] the association between 
the level of adherence and loss of response, leading to hospitalisa-
tion, surgery, and dose intensification or discontinuation of anti-
TNF agents in outpatients with IBD.
2. Patient and Methods
2.1. Patient population and design
Between May 2012 and May 2013, adult [age ≥ 18 years] ambulatory 
patients with an established diagnosis of IBD19,20 receiving infliximab 
[intravenous] or adalimumab [subcutaneous] as induction or main-
tenance treatment were invited to participate in the study. Patients 
were recruited from three university hospitals [University Medical 
Centre Utrecht, Leiden University Medical Centre, Maastricht 
University Medical Centre] and three general hospitals [Jeroen Bosch 
Hospital, ‘s Hertogenbosch; Diakonessenhuis, Utrecht; Onze Lieve 
Vrouwe Gasthuis, Amsterdam] in The Netherlands. At baseline, 
patients completed a baseline questionnaire, which included demo-
graphic data, clinical disease activity, treatment beliefs, illness per-
ceptions, and adherence behavior, as described below. Clinical data 
were collected from electronic medical records. Patients were then 
prospectively followed for 12 months. Clinical outcomes were also 
collected from electronic medical records. Local patient pharmacies 
were contacted for medication refills during follow-up. The study 
was centrally approved by the Ethics Committee of the University 
Medical Centre Utrecht. All patients signed informed consent.
2.2. Risk factors for non-adherence to anti-TNF  
agents
Potential risk factors for non-adherence to anti-TNF agents were 
derived from two systematic reviews.5,6 Demographic risk factors 
included gender, age, smoking status [current smoker, ex-smoker, 
non-smoker], and education level [low versus high]. Low education 
included no education, primary education, secondary education, and 
technical or professional school, whereas high education included 
higher vocational education and university.
Clinical risk factors included age at diagnosis, disease dura-
tion, disease localisation, perianal disease, concomitant medication 
[mesalazine, corticosteroids, immunomodulators], anti-TNF agent, 
and duration of anti-TNF treatment at enrolment. Clinical disease 
activity was measured with the validated patient-based Harvey-
Bradshaw Index [11 items, excluding question about abdominal 
mass]21,22 and the patient-based Simple Clinical Colitis Activity 
Index [9 items]23,24 for patients with CD and UC, respectively. 
A score more than 4 indicated clinically active disease. The patient-
based Harvey-Bradshaw Index consists of 11 items addressing 4 
domains, including general well-being [1 item], abdominal pain [1 
item], number of liquid stools per day [1 item], and extraintestinal 
manifestations [8 items: arthralgia, uveitis, erythema nodosum, aph-
thous ulcer, pyoderma gangrenosum, anal fissure, new fistula, and 
abscess]. As the third item of the clinician-based Harvey-Bradshaw 
Index [abdominal mass] requires a physical examination, this item 
was excluded.22
Behavioural risk factors included illness perceptions and treat-
ment beliefs. Illness perceptions were assessed with the Brief Illness 
Perception Questionnaire.25 This 9-item questionnaire explores the 
cognitive and emotional representations of illness across 8 dimen-
sions: Consequences, Timeline, Personal Control, Treatment Control, 
Identity, Concerns, Understanding, and Emotional Response. Items 
are assessed on an 11-point Likert scale, for example ‘How much 
does your illness affect your life?’: 0 [‘not at all’] – 10 [‘severely 
affects my life’]. Treatment beliefs were assessed with the Beliefs 
about Medicines Questionnaire specific [BMQ-specific].26,27 This 
questionnaire consists of two subscales assessing patients’ beliefs 
about the necessity of the prescribed medication for controlling their 
illness, and their concerns about the potential adverse consequences 
of taking it. For example: ‘My health at present depends on this 
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medicine’ or ‘I sometimes worry about becoming too dependent on 
this medicine’. Patients indicate their degree of agreement with each 
statement on a 5-point Likert scale, ranging from strongly disagree 
[1] to strongly agree [5]. A mean score for each subscale is calculated 
by dividing total scores by the number of items in the scale, result-
ing in a mean score range of 1–5 for both necessity [8 items] and 
concerns [9 items] scales.
2.3 Adherence measures
Adherence to anti-TNF agents was measured with an 8-item self-
reported measure [Morisky Medication Adherence Scale-8, MMAS-
8]28 and pharmacy refills. At baseline, patients were asked to fill out 
the MMAS-8. This tool addresses several factors of medication- taking 
behaviour, including failure to remember and problems with the com-
plexity of the anti-TNF regimen It has been reported to correlate well 
with patients’ adherence as measured with pharmacy refills in IBD.30 
A score less than 6 points is interpreted as low adherence, 6–7 points 
as medium adherence, and 8 points as high adherence.
Medication refills were assessed over 12  months. By tracking 
refills over a 12-month period, patients’ refill activity was aver-
aged and accounted for ‘medication hoarding’ and premature refills. 
Pharmacy refill adherence was calculated by dividing the number of 
days supplied within the refill interval [based on the dosing regimen] 
by the number of days in the actual refill interval over 12 months, 
and expressed as percentage. Pharmacy refills are considered a suit-
able ‘gold standard’ to measure patient adherence.30
2.4. Outcome measures
The main outcome measure included the association between adher-
ence to anti-TNF agents and loss of response. No exact definition 
of loss of response exist.31 In the present study, loss of response 
was defined by clinical worsening leading to IBD-related surgery 
[bowel resection, strictureplasty or ostomy, or perianal surgery30], 
IBD-related hospitalisation, or dose intensification or discontinua-
tion of anti-TNF agent. Dose intensification was defined as either 
an increase in dose (from 5 mg to 10 mg/kg for infliximab [IFX]; 
from 40 mg to 80 mg for adalimumab [ADA]) or as a decrease of the 
interval between infusions [ranging from 4 to 8 weeks] or injections 
[from every other week to every week]. At the physicians’ discre-
tion, trough serum concentrations of IFX or ADA were measured 
in patients with loss of response. Trough levels were measured by 
Sanquin, Amsterdam, The Netherlands, using an enzyme-linked 
immunosorbent assay [ELISA] as previously described.33 Trough 
levels of IFX <3  µg/ml and of ADA < 5  µg/ml were considered 
subtherapeutic.34,35
2.5. Statistical analysis
Data analyses were performed using SPSS 20.0 and SAS 9.2. 
Descriptive statistics were used to characterise IBD patients. Means 
and medians were reported with a standard deviation [SD] and inter-
quartile range [IQR], respectively. Comparisons between adherent 
and non-adherent IBD patients according to MMAS-8 and phar-
macy refills [MPR] were analysed with Student’s-t test for contin-
uous variables and χ2 test for dichotomous variables. Association 
between MMAS-8 and MPR percentage was assessed by means 
of Spearman’s correlation analysis. In order to determine factors 
associated with non-adherence, we performed univariate logistic 
regression analysis with demographic, disease, and behavioural 
characteristics. Characteristics that were associated [p < 0.10] with 
non-adherence following univariate analysis were included in the 
multivariate logistic regression analyses to identify independent risk 
factors for adherence. Cox proportional hazards regression analysis 
was performed to determine the association between adherence and 
time to loss of response. Tests for trends in loss of response across 
categories of MPR percentage [0–40, 40–60, 60–80, 80–100%] were 
conducted using the median value in each category as a continu-
ous variable in the linear regression models. We estimated that after 
12 months, 70% of all anti-TNF users will have maintained clinical 
response.36,37 With an alpha of 0.05 and a power of 90%, we were 
able to have an area under the receiver operating curve of 0.75 [with 
standard error of 0.05] if we included 32 anti-TNF users without 
clinical response. Based on 70% maintained clinical response, the 
inclusion of 107 anti-TNF users was required. After adjustment for 
missing values and loss to follow-up, we decided to include a total 
of 130 anti-TNF users.
3. Results
3.1. Patient population
Between May 2012 and May 2013, 128 patients were prospectively 
enrolled and 12 patients declined to participate [Figure 1]. Patients 
who declined to participate had a lower mean age [27.3 ± 7.7 versus 
36.6 ± 13.6 years, p = 0.02] as compared with patients who did par-
ticipate [Table 1]. There were no statistically significant differences 
between groups with regard to relevant demographic and clinical 
characteristics. Obviously, data on clinical disease activity, illness 
perceptions, and treatment beliefs of non-responders could not be 
obtained. Of the 128 patients, 104 [81%] had CD and 24 [19%] 
had either UC or IBD-unclassified, with a mean age of 36.6 [± SD 
13.6] years, and a median disease duration of 8 [IQR 4–14] years; 
66 [46%] and 62 [54%] patients received infliximab and adali-
mumab, respectively; 62 [47%] patients were concomitantly treated 
with immunosuppressive agents. Overall, 27/61 [44%] adalimumab 
users and 33/67 [49%] infliximab users were concomitantly treated 
140 eligible patients
12 (9%) patients declined
128 patients included
127 patients with MMAS-8a
scores
12 patients lost to FUb
(9%), 16 patients without
pharmacy rells (13%)
Baseline (table 1)
Risk factor analysis low
adherence (g. 3)
Risk factor analysis non-
adherence (g. 2) and loss
of response (Supplementary
table 2)
99 patients with pharmacy
rells
Figure  1. Flow-chart. [a] Modified Morisky Adherence Scale, 8 items; [b] 
follow-up.
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with immunosuppressive agents [p = 0.60]; 41 [32%] patients had 
clinically active disease as measured with the clinical index score. 
During follow-up, 12 patients [9.4%] were lost to follow-up because 
of no response to induction treatment [4], death [1], transfer [3], 
or unknown [4]; 12-month pharmacy refills were available for 99 
patients.
3.2. Adherence
Of 128 patients, 127 filled-out the MMAS-8. The median MMAS-8 
score was 7.00 [IQR 5.75–7.75] [Table 1]. Patients who were lost 
to follow-up did not have a significantly different median MMAS-8 
score [7.75, IQR 6.00–8.00 versus 7.00, IQR 5.75–7.75; p = 0.15]; 
36 [28%] patients were ‘low adherer’, 61 [48%] ‘medium adherer’, 
and 30 [24%] ‘high adherer’. Low adherence to infliximab and adali-
mumab was reported in, respectively, 16/66 [24%] and 20/61 [33%] 
of patients [p =0 .33]; 12-month pharmacy refills were available 
for 99 patients; 25 [25%] patients were non-adherent to anti-TNF 
agents. Non-adherence to infliximab and adalimumab was reported 
in, respectively, 4/50 [8%] and 21/49 [43%] of patients [p < 0.01]. 
The correlation coefficient between the MMAS-8 and MPR percent-
age was 0.28 [p = 0.014].
3.3. Risk factors of non-adherence [MPR < 80%] and 
low adherence according MMAS-8
The results of the univariate analyses are shown in Supplementary 
Tables 1 and 2, available as Supplementary data at ECCO-JCC 
online. Independent risk factors for non-adherence according to 
pharmacy refills were adalimumab use [OR 10.1, 95% CI 2.62–
40.00], shorter timeline perception, i.e. perceptions of IBD as an 
acute episodic disease [OR 0.60, 95% CI 0.38–0.96], and stronger 
emotional response, i.e. negative emotions resulting from IBD [OR 
1.16, 95% CI 1.02–1.31] [Figure  2]. Although CD patients were 
more likely to be non-adherent in univariate analysis [OR 6.10, 95% 
CI 0.76–50.00], this association disappeared in the multivariate 
analysis [OR 2.68, 95% CI 0.24–29.42]. Independent risk factors 
for low adherence according to the MMAS-8 were a weaker illness 
identity, i.e. less symptoms associated with IBD [OR 0.66, 95% CI 
0.51–0.85], and a stronger emotional response [OR 1.48, 95% CI 
1.18–1.87]. There was a trend towards a statistically significant and 
negative association between induction therapy and low adherence 
[OR 0.43, 95% CI 0.17–1.07] [Figure 3].
3.4. Association between adherence and loss of 
response
During a median follow-up of 1.4 years [IQR 0.8–2.2] 56 of 116 
[48%] IBD patients lost response to an anti-TNF agent [46/100 
patient-years], which resulted in IBD-related surgery in 11 patients, 
hospitalisation in 3 patients, and dose intensification and discon-
tinuation in 42 patients. Trough levels were measured in 36 of 56 
[64%] IBD patients, including 19 patients on IFX and 17 patients on 
ADA; 11 of 19 [58%] IFX users and 8 of 17 [47%] ADA users had a 
subtherapeutic trough level with a median of, respectively, 2.0 µg/ml 
[IQR 0.9–9.0] and 4.8 µg/ml [IQR 2.0–8.5]. In univariate analysis, 
risk factors for loss of response were Crohn’s disease [OR 2.58, 95% 
CI 1.37–4.87], clinically active disease at baseline [OR 2.12, 95% 
CI 1.20–3.77], co-treatment with corticosteroids [OR 3.41, 95% CI 
1.63–7.12], and low MPR percentage [OR 0.14, 95% CI 0.03–0.63]. 
Co-treatment with an immunosuppressive agent was not associated 
Table 1. Patient characteristics [responders: n = 128; non-responders: n = 12].
Characteristic: Responders: Nonresponders: p value
Age, mean [± SD] 36.6 [13.6] 27.3 [7.7] 0.02
Female gender, n [%] 71 [55] 4 [33] 0.23
Smoking, n [%] 25 [20]
Low education, n [%] 80 [63]
Diagnosis, n [%]
 Crohn’s disease 104 [81] 11 [92] 0.47
 Ulcerative colitis, IBD-u 24 [19] 1 [8] 0.47
Disease duration, median [IQR] 8 [4–14]
IBD localisationa
 Large bowel 29 [28] 3 [27] 0.55
 Small bowel 20 [19] 3 [27] 0.42
 Both large and small bowel 55 [53] 5 [45] 0.76
Clinical active disease, n [%] 41 [32]
Perianal disease, n [%] 74 [71]
Anti-TNF agent, n [%]
 Infliximab 66 [52] 8 [67] 0.38
 Adalimumab 62 [48] 4 [33] 0.38
Concomitant medication, n [%]
 5-ASA 22 [17] 2 [17] 1.00
 Corticosteroid 21 [16] 1 [8] 0.69
 Immunosuppressive agent 62 [48] 4 [33] 0.38
MMAS-8b score, median [IQR]c 7.00 [5.75–7.75]
 <6 [‘low adherer’], n [%] 36 [28]
 6–8 [‘medium adherer’], n [%] 61 [48]
 8 [‘high adherer’], n [%] 30 [24]
SD, standard deviation; IBD-u, inflammatory bowel disease unclassified; IQR, interquartile range; TNF, tumour necrosis factor; 5-ASA, 5-aminosalicylates.
aCrohn’s disease patients.
bModified Morisky Adherence Scale-8.
c1 missing value.
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with loss of response [OR 0.88, 95% CI 0.48–1.61]. An increase in 
MPR percentage was parallelled by a significant [p = 0.013] decrease 
in the proportion loss of response [Figure 4]. Factors that were inde-
pendently associated with loss of response included co-treatment 
with corticosteroids [OR 2.93, 95% CI 1.16–7.41] and low MPR 
percentage [OR 0.08, 95% CI 0.02–0.42].
4. Discussion
In this 12-month observational study, non-adherence rates were sig-
nificantly higher in patients treated with adalimumab than with inf-
liximab. Non-adherence to anti-TNF agents was strongly determined 
by adalimumab use and—to a minor extent—by negative beliefs 
about how IBD affects one’s emotional well-being [i.e. a stronger 
emotional response]. Additionally, we found that non-adherence was 
significantly associated with loss of response to anti-TNF agents.
To our knowledge, this is the first study exploring the influence 
of illness perceptions on adherence to anti-TNF agents and prospec-
tively examining the association between adherence to anti-TNF 
agents and loss of response. The overall non-adherence rate for anti-
TNF agents was 25% [defined as a medication possession ratio < 
80%], which is similar to the rates reported by two large system-
atic reviews [17% to 45%].10,11 Non-adherence rates were higher 
for adalimumab than for infliximab according to both the Modified 
Morisky Adherence Scale-8 [MMAS-8] [adalimumab 33% vs inflixi-
mab 24%] and the pharmacy refills [adalimumab 43% vs infliximab 
8%]. The significantly higher non-adherence rate for adalimumab 
may be explained by the fact that adalimumab is self-administered, 
whereas infliximab is administered intravenously by a healthcare 
professional in a controlled setting. Although one might presume 
that adalimumab users are more likely to have a non-adherent 
behaviour, this was not found with the MMAS-8 tool. Additionally, 
there were no significant differences between adalimumab and 
infliximab users with regard to illness perceptions and treatment 
beliefs, which could have explained the difference in non-adherence 
rates. Notwithstanding, confounding by indication may still have 
occurred, as physicians are more likely to prescribe infliximab to 
patients with possibly unfavourable medication-taking behaviour.
We found that the MMAS-8 tool correlated significantly with 
patients’ refill behaviour. Yet, with a correlation coefficient of only 
0.28, this correlation was weak, limiting the use of the MMAS-8 
as a useful screening tool to predict patients’ medication adherence 
behaviour. However, the MMAS-8 may be a useful tool to assess 
patients’ reasons for non-adherence and differentiate between inten-
tional and unintentional non-adherence.38
This finding is in line with a study that examined the correlation 
between the MMAS-8 tool and pharmacy refills among 150 IBD 
patients receiving different drug classes, including 5-aminosalicylates 
[ASA], budesonide, immunomodulators, and anti-TNF agents.30 
A significant association between the MMAS-8 tool and pharmacy 
refills was found with regard to immunomodulators [r  =  0.26, 
p = 0.02], but not to anti-TNF agents [r = -0.04, p = 0.85]. In con-
trast, other studies which excluded patients receiving anti-TNF 
agents, observed a significant association between the MMAS-8 tool 
and pharmacy refills.29,39 These differences may be explained by the 
fact that the MMAS-8 tool was originally developed in patients on 
daily medication. Additionally, several questions on the MMAS-8 
simply do not apply for intravenous medication [infliximab], for 
example: ‘Have you cut back your medication without telling your 
doctor?’
In order to improve medication adherence, researchers and phy-
sicians increasingly focus on modifiable factors such as frequency 
of dosing, route of administration, measures to reduce anxiety and 
depression, and beliefs about medication. Beliefs about medication 
may play a key role in determining non-adherence. A cross-sectional 
study of 1871 IBD patients reported more doubts about the personal 
need for maintenance treatment and more concerns about poten-
tial adverse effects in non-adherent patients [according to the four-
item Medication Adherence Report Scale].28 These findings were 
confirmed by a cross-sectional study of 356 IBD patients in which 
adherent patients had a higher belief of necessity to take medica-
tion and a trend towards lower concerns about medication.17 There 







Figure  2. Independent risk factors of low adherence (Modified Morisky 
Adherence Scale [MMAS]-8 score < 6].
CD vs. UC









Figure 3. Independent risk factors of non-adherence (medication possession 


































Figure 4. Association between medication possession ratio [MPR] category 
and proportion of patients with loss of response [%].
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beliefs about medication and non-adherence in the present study. 
As non-adherent patients in our cohort had a trend towards more 
concerns about potential adverse effects, our study might have been 
underpowered to detect significant differences between adherent 
and non-adherent patients with regard to beliefs about medication. 
Interestingly, we demonstrated in our study that illness percep-
tions, in particular negative perceptions about how IBD affects a 
patient’s emotional well-being [i.e. emotional response] and percep-
tions of IBD as an acute episodic disease [i.e. timeline perception], 
were significantly associated with non-adherence. This concurs with 
previous studies showing a negative impact of emotional responses 
[feelings of anxiety, anger, and depression] on medication adherence 
in patients with hypertension.40,41 Additionally, a prospective study 
of 198 adult patients with allergic asthma reported a significantly 
lower adherence in patients who perceived their asthma as only pre-
sent when they experienced symptoms.42 This finding corroborates 
the Common Sense Model of self-regulation, in which it is stated 
that individual’s personal beliefs about an illness [here: IBD] play a 
major role in the adjustment to the illness, i.e. taking the medication 
as prescribed.19,43
Finally, we demonstrated that adherence was linearly associated 
with loss of response, i.e. every 10% increase in MPR corresponded 
with a 24% decreased risk of losing response to an anti-TNF agent. 
In contrast to previous studies in patients with dyslipidaemia and 
HIV/AIDS, we have not identified a threshold adherence level above 
which the risk of losing response significantly decreased.8,9 This may 
be partly due to the complex pharmacological metabolism of anti-
TNF agents [e.g. production of anti-TNF antibodies and routes of 
administration] in respect to the more ‘simple’ oral lipid-lowering 
and antiretroviral drugs. Additionally, in the present study adherence 
was linked to clinical outcomes, whereas previous studies used ‘inter-
mediate’ outcomes such as virological failure and lipid reduction.
This study has several strengths. First, this study was powered 
to detect a statistically significant association between adherence 
and loss of response. Second, two methods of adherence measure-
ment, i.e. the MMAS-8 tool and pharmacy refills, were combined 
in order to maximise accuracy. Third, patients were prospectively 
followed for 12 months, which enabled assessment of predictors of 
non-adherence and loss of response. Fourth, patients were included 
from both university and general hospitals, thereby, in our view, reli-
ably representing the average IBD patient in The Netherlands.
Some limitations of this study need to be addressed as well. First, 
although the MMAS-8 tool was modified in order to measure adher-
ence to anti-TNF agents, some questions may not be applicable to 
non-oral medication. Second, as trough levels were not systemati-
cally measured in patients with loss of response, we could not relia-
bly assess the association between trough levels and loss of response. 
Third, although the non-adherence rate found in our study is in 
line with previous studies, the Hawthorne effect [in which patients 
improve their medication-taking behaviour in response to their 
awareness of being observed]44 could not be completely excluded. 
Consequently, the non-adherence to TNF-inhibitors in clinical prac-
tice might even be higher.
In conclusion, our results show a linear association between 
adherence to anti-TNF agents and loss of response. Additionally, 
adherence is substantially lower in patients treated with adali-
mumab, in patients with negative beliefs about how IBD affects one’s 
emotional well-being, and with a shorter timeline perception. As ill-
ness perceptions and beliefs about medication are potentially modi-
fiable factors, they may provide a relevant target for interventions 
aimed at improving adherence and other health outcomes. These 
interventions might have a far greater impact on health outcomes 
than any treatment itself.45 Future studies should focus on the use of 
trough levels as a reliable measure of adherence and on the develop-
ment of adherence-enhancing interventions targeted at modifiable 
factors such as treatment and illness beliefs.
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